Nancy Thornberry
Director/Board Member chez SCHRÖDINGER, INC.
Fortune : 904 480 $ au 31/03/2024
Profil
Nancy A.
Thornberry is the founder and currently holds the position of Director, Chairman-Research & Development at Kallyope, Inc., which was founded in 2015.
She is also currently serving as an Independent Director at Vertex Pharmaceuticals, Inc. since 2023, Director at Abide Therapeutics, Inc. since 2014, Director at Intarcia Therapeutics, Inc. since 2013, Independent Director at Schrödinger, Inc. since 2019, Director at New York Genome Center, Independent Director at Denali Therapeutics, Inc. since 2021, Scientific Advisor at Hatteras Venture Partners, and Advisor at GV Management Co. LLC.
Ms. Thornberry previously worked at Merck & Co., Inc. from 2004 to 2013, where she held the position of Senior VP, Head-Diabetes & Endocrinology from 2011 to 2013.
She also worked at Merck Research Laboratories Massachusetts LLC as a Principal.
Ms. Thornberry completed her undergraduate degree at Muhlenberg College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/12/2023 | 1 136 ( 0,00% ) | 474 859 $ | 31/03/2024 | |
DENALI THERAPEUTICS INC.
0,01% | 01/06/2023 | 12 713 ( 0,01% ) | 260 871 $ | 31/03/2024 |
SCHRODINGER, INC.
0,01% | 15/06/2023 | 6 250 ( 0,01% ) | 168 750 $ | 31/03/2024 |
Postes actifs de Nancy Thornberry
| Sociétés | Poste | Début |
|---|---|---|
| SCHRÖDINGER, INC. | Director/Board Member | 24/09/2019 |
| DENALI THERAPEUTICS INC. | Director/Board Member | 08/01/2021 |
| VERTEX PHARMACEUTICALS INCORPORATED | Director/Board Member | 05/12/2023 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Director/Board Member | 01/12/2013 |
Abide Therapeutics, Inc.
 Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Director/Board Member | 29/07/2014 |
Kallyope, Inc.
 Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | Founder | 01/11/2015 |
GV Management Co. LLC
 GV Management Co. LLC Investment ManagersFinance GV Management Co LLC (Google Ventures) is a venture capital firm, a subsidiary of Google LLC founded in 2009 by Bill Maris. The firm is headquartered in Mountain View, California with an additional office in San Francisco, Boston, New York and London. | Consultant / Advisor | - |
Hatteras Venture Partners
 Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | Consultant / Advisor | - |
New York Genome Center
 New York Genome Center Miscellaneous Commercial ServicesCommercial Services New York Genome Center operates as an independent, nonprofit academic research institution that provides genomic research. It provides research on neurodegenerative disease, neuropsychiatric disease, and cancer. The company was founded in 2011 and is headquartered in New York, NY. | Director/Board Member | - |
Anciens postes connus de Nancy Thornberry
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Nancy Thornberry
| Muhlenberg College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| SCHRÖDINGER, INC. | Technology Services |
| DENALI THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Health Technology |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | Finance |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The private company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Health Technology |
GV Management Co. LLC
GV Management Co. LLC Investment ManagersFinance GV Management Co LLC (Google Ventures) is a venture capital firm, a subsidiary of Google LLC founded in 2009 by Bill Maris. The firm is headquartered in Mountain View, California with an additional office in San Francisco, Boston, New York and London. | Finance |
New York Genome Center
New York Genome Center Miscellaneous Commercial ServicesCommercial Services New York Genome Center operates as an independent, nonprofit academic research institution that provides genomic research. It provides research on neurodegenerative disease, neuropsychiatric disease, and cancer. The company was founded in 2011 and is headquartered in New York, NY. | Commercial Services |
Kallyope, Inc.
Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | Health Services |
